Tocilizumab in Subjects with Giant Cell Arteritis: GiACTA

Study Findings: This study showed that weekly tocilizumab (Actemra®) treatment, initially in combination with a 6-month steroid taper, enabled significantly more patients with GCA to achieve sustained remission while also reducing steroid exposure compared with taking steroids alone. View Publication.

ClinicalTrials.gov ID: NCT01791153

Study Dates: 2013-2018

Disease(s): Giant Cell Arteritis (GCA)